Trial Search Results

Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma

RATIONALE: Vaccines made from a person's cancer cells may make the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood and may stimulate the immune system in different ways and stop cancer cells from growing.

PURPOSE: This phase II trial is studying how well giving vaccine therapy together with GM-CSF works in treating patients with progressive B-cell non-Hodgkin's lymphoma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Favrille

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine
  • Biological: sargramostim

Phase:

Phase 2

Eligibility


DISEASE CHARACTERISTICS:

   - Histologically confirmed follicular B-cell non-Hodgkin's lymphoma (NHL)

      - Grade 1, 2, or 3

   - Progressive disease AND did not receive autologous immunoglobulin idiotype-KLH
   conjugate vaccine (FavId™) while enrolled on protocol FAV-ID-06

   - Meets 1 of the following criteria:

      - Received salvage therapy after completion of protocol FAV-ID-06

         - At least 4 weeks, but no more than 4 months, since prior salvage therapy

      - Did not receive salvage therapy after completion of protocol FAV-ID-06

         - At least 4 weeks, but no more than 4 months, since completion of prior
         treatment on protocol FAV-ID-06

   - No history of CNS lymphoma OR meningeal lymphomatosis

PATIENT CHARACTERISTICS:

Age

   - 18 and over

Performance status

   - ECOG 0-2

Life expectancy

   - Not specified

Hematopoietic

   - Not specified

Hepatic

   - Not specified

Renal

   - Not specified

Cardiovascular

   - No history of congestive heart failure

Pulmonary

   - No history of compromised pulmonary function

Other

   - Not pregnant or nursing

   - Negative pregnancy test

   - Fertile patients must use effective contraception

   - HIV negative

   - No active bacterial, viral, or fungal infection

   - No psychiatric disorder

   - No other serious nonmalignant disease that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

   - See Disease Characteristics

   - No prior allogeneic transplantation*

   - No prior rituximab regimen* other than that administered on protocol FAV-ID-06
   (rituximab 375 mg/m^2 IV weekly for 4 weeks)

Chemotherapy

   - No prior purine analogues* (e.g., fludarabine or cladribine)

Endocrine therapy

   - No prior or concurrent steroids (e.g., steroid doses in excess of daily replacement)

Radiotherapy

   - Not specified

Surgery

   - Not specified

Other

   - Recovered from prior salvage therapy

   - No prior or concurrent immunosuppressive therapy

   - No prior investigational agents*

   - No other concurrent antilymphoma therapy NOTE: *As salvage therapy administered
   between completion of protocol FAV-ID-06 and enrollment onto this study

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mayita Romero
6507256452
Not Recruiting